Latest Breaking News On - Sun yat sen university cancer center - Page 6 : vimarsana.com

Adding Fruquintinib to Paclitaxel Improves PFS in Gastric, GEJ Cancer

Fruquintinib plus paclitaxel could be a second-line treatment option for patients with gastric or gastroesophageal junction cancer, according to researchers. Fruquintinib plus paclitaxel could be a second-line treatment option for patients with gastric or GEJ cancer, according to researchers.

Second-Line Fruquintinib Plus Paclitaxel Significantly Improves PFS But Not OS in Advanced Gastric or GEJ Adenocarcinoma

Fruquintinib/paclitaxel significantly improved PFS but not OS vs paclitaxel alone in the second-line treatment in patients with advanced gastric cancer.

Mixed Results in Advanced Gastric/GEJ Cancer With Add-On Fruquintinib

Significant improvement in PFS, but not OS, versus chemo alone in the second-line setting

Results of Phase II Study on Qilu Pharmaceutical's Novel Drug QL1706 Published in Signal Transduction and Targeted Therapy

/PRNewswire/ On January 29th, the results of the phase II study on Qilu Pharmaceutical s novel anticancer drug iparomlimab and tuvonralimab (QL1706) were.

InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China